GLP-1 Agonist Salt Forms and Crystals for Oral Diabetes Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing GLP-1 receptor agonists, such as peptidic GLP-1 receptor agonists like liraglutide and exenatide, suffer from poor oral bioavailability and inconvenient administration, while small molecule agonists with good oral bioavailability are desirable for treating diabetes.
Innovation Solution
Development of pharmaceutically acceptable salts and crystalline forms of a novel GLP-1 receptor agonist, specifically 2-((4-((S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydrobenzo[b][1,4]dioxan-5-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, including various alkali and acid ratios and crystalline forms, to enhance physical and chemical properties for improved pharmaceutical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptidic GLP-1 receptor agonists are used, then blood glucose control is improved, but oral bioavailability is poor and administration is inconvenient
Solution Approach 1:
The patent changes the chemical structure from peptidic to small molecule compounds, fundamentally altering the molecular parameters to achieve both glucose control efficacy and oral bioavailability. The small molecule structure allows for better absorption while maintaining GLP-1 receptor agonist activity.
Solution Approach 2:
The patent develops composite salt forms of the small molecule agonist with various counterions (sodium, potassium, calcium, magnesium salts, and organic acid salts). These composite salt structures improve solubility, stability, and oral bioavailability while maintaining the therapeutic effect on blood glucose control.
2Reliability
If salt forms are developed to improve physical and chemical properties, then pharmaceutical properties are enhanced, but the complexity of salt selection and characterization increases
Solution Approach 1:
The patent systematically varies the counterion parameters to create different salt forms, each with optimized physical and chemical properties. By changing the counterion (Na+, K+, Ca2+, Mg2+, or organic acid anions), the patent achieves different solubility, stability, and crystallization characteristics while following a consistent development approach.
Solution Approach 2:
The patent focuses on developing a limited number of pharmaceutically acceptable salt forms with well-defined characteristics rather than exploring all possible salt combinations. This selective approach to salt form development reduces characterization complexity while still providing multiple options for optimizing pharmaceutical properties.
3Ease of manufacture
If crystalline forms are studied for industrial production suitability, then manufacturing stability is improved, but the time and resources required for polymorph screening increase
Solution Approach 1:
The patent performs preliminary crystallization studies during the salt form development phase, screening multiple solvents and conditions to identify stable crystalline forms before proceeding to industrial production. This advance work on polymorph characterization during salt development reduces the need for extensive polymorph screening later in the development process.
Solution Approach 2:
The patent systematically varies crystallization parameters (solvent type, temperature, pH, evaporation rate) to identify stable polymorphic forms of each salt. By controlling these parameters during salt form development, the patent establishes reproducible crystalline structures that are suitable for industrial production while minimizing the need for subsequent polymorph optimization.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Provided are a pharmaceutically acceptable salt and a crystalline form of a GLP-1 receptor agonist and a preparation method therefor. Specifically, provided are a pharmaceutically acceptable salt and a crystalline form of a compound 2-((4-((S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydrobenzo[b][1,4] dioxane-5-yl)piperidin-1-yl)methyl)-1-(((S)-oxe-tane-2-yl)methyl)-1H-benzo[d]imidazole-6-formic acid.